Genetic landscape of clear cell endometrial cancer and the era of precision medicine

Huang, Gloria S.; Santin, Alessandro D.

doi:10.1002/cncr.30743

Cited by 4 publications

(2 citation statements)

References 20 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clear cell endometrial cancer (CCEC) is an uncommon but aggressive histologic type that accounts for 1%-6% of endometrial cancer (EC), and characterized by poorer prognosis and chemotherapy resistance ( 1 ). A clear cell endometrial carcinoma usually features HNF1β positive, Napsin A positive, WT1 negative and estrogen receptor (ER)/progesterone receptor (PR) negative ( 2 ).…”

Section: Introductionmentioning

confidence: 99%

The role of TCGA molecular classification in clear cell endometrial carcinoma

Tang

2023

Front. Oncol.

View full text Add to dashboard Cite

Clear cell endometrial carcinoma (CCEC) represents a relatively rare and heterogeneous entity. Based on The Cancer Genome Atlas (TCGA) molecular classification, the risk stratification and management of endometrial cancer (EC) have been improved. Although the relationship of CCEC with the TCGA classification is less well understood, data has emerged to suggest that molecular classification plays an important role in the prognosis and management of CCEC. Most of patients with CCEC are characterized by p53abn or NSMP type and the prognosis of these patients is poor, whereas those with MMRd or POLEmut seem to have a favorable prognosis. Adjuvant therapy is recommended in CCEC with p53abn and NSMP. Advanced/recurrent CCEC with MMRd benefit much more from immune checkpoint inhibitors after the failure of platinum-based chemotherapy. In addition, bevacizumab plus chemotherapy upfront seems to improve outcomes of advanced/recurrent patients whose tumors harbored mutated TP53, including CCECs with p53abn. Further studies which exclusively recruit CCEC are urgently needed to better understand the role of molecular classification in CCEC. This review will provide an overview of our current understanding of TCGA classification in CCEC.

show abstract

Section: Introductionmentioning

confidence: 99%

The role of TCGA molecular classification in clear cell endometrial carcinoma

Tang

2023

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Endometrial clear cell carcinoma (ECCC) is a rare type of EC. Only 1%-5% of ECs are diagnosed as ECCC (2,3).…”

Section: Introductionmentioning

confidence: 99%

Identifying clinical features and molecular characteristics of the endometrial clear cell carcinoma

Cai,

Han,

Guo

2023

Front. Oncol.

View full text Add to dashboard Cite

ObjectiveThe aim of this study was to verify TCGA subtypes in endometrial clear cell carcinoma (ECCC) and determine their clinical and molecular characteristics.MethodsWe summarized and compared the clinical features of 28 clear cell carcinoma and 112 endometrioid carcinoma patients. Of the 28 ECCCs, 19 underwent TCGA classification, and other markers (ER, PR, ARID1A, ARIB1B, TAF1, and HER-2) were also detected by IHC, and outcomes were assessed.ResultsCompared to endometrioid carcinoma, ECCC had an older age of onset (median age, 64.5 years, range 31–81 years), higher rate of myometrial invasion (42.8% vs. 21.5% in endometrioid carcinoma), LVSI (33% vs. 16%), and more advanced FIGO stage. Among the ECCCs, LVSI was a poor prognostic factor. TCGA classification was performed for 19 ECCCs: two POLEmut cases (10.5%), three MMRd (15.8%), 11 p53wt (57.9%), and three p53abn (15.8%). Of the 19 ECCCs, six (31.6%) showed HER-2 positive expression, and eight (42.1%) had TAF1 expression loss. ECCCs possessed HER-2 and TAF1 expression had worse outcomes.ConclusionOur study summarized the clinical features of ECCC. The outcomes of patients with ECCC with TCGA subtypes differed from those of patients with endometrioid carcinoma. HER-2 and TAF1 may be new prognostic factors.

show abstract

A potpourri of pathogenetic pathways in endometrial carcinoma with a focus on Lynch Syndrome

Wadee

Grayson

2019

Annals of Diagnostic Pathology

View full text Add to dashboard Cite

Genetic landscape of clear cell endometrial cancer and the era of precision medicine

Abstract: The increased understanding of the genetic landscape of clear cell endometrial cancer should guide the development of precision medicine strategies to improve survival. See also pages 3261‐8.

Cited by 4 publications

References 20 publications

The role of TCGA molecular classification in clear cell endometrial carcinoma

The role of TCGA molecular classification in clear cell endometrial carcinoma

Identifying clinical features and molecular characteristics of the endometrial clear cell carcinoma

A potpourri of pathogenetic pathways in endometrial carcinoma with a focus on Lynch Syndrome

Contact Info

Product

Resources

About